The hope and reality of long-acting hemophilia products (Q37990479)

26 August 2017

title

The hope and reality of long-acting hemophilia products (English)

1 reference

26 August 2017

0 references

Steven W Pipe

1

1 reference

26 August 2017

publication date

3 March 2012

1 reference

American Journal of Hematology

26 August 2017

published in

1 reference

26 August 2017

volume

87 Suppl 1

1 reference

26 August 2017

page(s)

S33-9

1 reference

Back to the future: a recent history of haemophilia treatment

26 August 2017

cites work

1 reference

Haemophilia care then, now and in the future

21 January 2018

1 reference

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

21 January 2018

1 reference

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

21 January 2018

1 reference

WFH--the cornerstone of global development: 45 years of progress

21 January 2018

1 reference

A study of reported factor VIII use around the world

21 January 2018

1 reference

A study of reported factor IX use around the world

21 January 2018

1 reference

Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008.

21 January 2018

1 reference

Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008.

21 January 2018

1 reference

Special lectures in haemophilia management.

21 January 2018

1 reference

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.

21 January 2018

1 reference

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

1 reference

Improved recombinant protein yield using a codon deoptimized DHFR selectable marker in a CHEF1 expression plasmid

21 January 2018

1 reference

Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide

21 January 2018

1 reference

Purification of recombinant DNA-derived factor IX produced in transgenic pig milk and fractionation of active and inactive subpopulations

21 January 2018

1 reference

Functional factor VIII made with von Willebrand factor at high levels in transgenic milk

21 January 2018

1 reference

Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.

21 January 2018

1 reference

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

21 January 2018

1 reference

A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia

21 January 2018

1 reference

Current and future approaches to inhibitor management and aversion

21 January 2018

1 reference

Future directions in hemostasis: normalizing the lives of patients with hemophilia

21 January 2018

1 reference

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

21 January 2018

1 reference

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

21 January 2018

1 reference

Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.

21 January 2018

1 reference

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring

21 January 2018

1 reference

Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease

21 January 2018

1 reference

Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels

21 January 2018

1 reference

Extending half-life in coagulation factors: where do we stand?

21 January 2018

1 reference

Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease

21 January 2018

1 reference

Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients

21 January 2018

1 reference

Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice

21 January 2018

1 reference

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes

21 January 2018

1 reference

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.

21 January 2018

1 reference

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

21 January 2018

1 reference

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

21 January 2018

1 reference

Prolonged activity of factor IX as a monomeric Fc fusion protein

21 January 2018

1 reference

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

21 January 2018

1 reference

A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing

21 January 2018

1 reference

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

21 January 2018

1 reference

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.

21 January 2018

1 reference

Progress in the treatment of bleeding disorders

21 January 2018

1 reference

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

21 January 2018

1 reference

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

21 January 2018

1 reference

Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects

21 January 2018

1 reference

Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects

21 January 2018

1 reference

Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa

21 January 2018

1 reference

Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study

21 January 2018

1 reference

Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.

21 January 2018

1 reference

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review

21 January 2018

1 reference

Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies

21 January 2018

1 reference

21 January 2018

1 reference

Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII.

21 January 2018

1 reference

Factor VIII inhibitors in previously treated hemophilic patients

21 January 2018

1 reference

Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives

21 January 2018

1 reference

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients

21 January 2018

1 reference

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23146

1 reference

26 August 2017

1 reference